EZH2 and central nervous system cancer: Aberrant EZH2 expression or mutations play pivotal roles in tumor malignant progression, exhibiting high expression in various solid tumors such as glioma and breast cancer, thereby promoting tumor occurrence and development (Paskeh et al. 2022).